Answers are grounded in this paper and cite their sources.
Antihistamines target the histamine H1 receptor. The affinity of this interaction defines their activity and, more importantly, their adverse effects. In recent years, however, some antihistamines have demonstrated a direct influence on inflammatory events, aside from their antiallergic properties. Although still unclear, these effects seem both H1 receptor-dependent and -independent. The available evidence reveals that some antihistamines have a role in early-phase reactions through the inhibition of the release of mediators such as histamine and tryptase but may also modulate late-phase allergic reactions by inhibiting eosinophil and neutrophil chemotaxis, activation, and survival. While some antihistamines have shown efficacy in reducing cytokine levels and inflammatory cell migration, these effects are often achieved at supratherapeutic doses, limiting their clinical application. Rupatadine, a second-generation antihistamine, has demonstrated broad inhibitory effects on several proinflammatory cytokines, such as IL-5, IL-6, IL-8, TNF-a, and GM-CSF. More importantly, there is evidence of a dual role for rupatadine, being both an H1 receptor antagonist and a PAF inhibitor. In this sense, the MASPAF study was essential in demonstrating the anti-PAF activity of rupatadine in human mast cells, with subsequent studies confirming its efficacy in both allergic rhinitis and chronic spontaneous urticaria. The aim of this narrative review is to summarize the available evidence on currently prescribed antihistamines, focusing on their mechanism of action and potential anti-inflammatory effects.
No takes yet. Share an insight, caveat, or question.
Fuente et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: